Atopic deRMAtitis DiseAse registry of ADult and adolescent patients initiating or switching systemic treatments (ARMADA-AD)

Atopic deRMAtitis DiseAse registry of ADult and adolescent patients initiating or switching systemic treatments (ARMADA-AD) - ARMADA-AD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030260092

Enrollment

1000

Registered

2026-04-27

Start date

2026-04-27

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients aged >=12 years at the time of consent - Confirmed diagnosis of AD, of any severity, according to the Investigators assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20 - Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral JAK inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) - Signed informed consent for registry participation by the patient or parent-legal representative and assent by the patient appropriate to the patients age, including willingness to participate in long-term follow-up

Exclusion criteria

Exclusion criteria: - Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care - Insufficient understanding of the study by the patient and-or parent/guardian

Design outcomes

Primary

Measure	Time frame
To describe the utilization patterns of systemic therapy for atopic dermatitis (AD) from baseline and over the follow-up period To describe clinical outcomes of treatment with systemic therapy for AD measured using clinical reported outcomes (ClinROs) and patient-reported outcomes (PROs) from baseline and over the follow-up period	—

Secondary

Measure	Time frame
To describe participant sociodemographic and clinical characteristics at baseline To describe quality of life, depression, productivity, and treatment satisfaction while being treated with systemic therapy for AD using PROs from baseline and over follow-up To describe health care resource utilization from baseline and over the follow-up period To evaluate selected comorbid atopic and non-atopic conditions at baseline and over the follow-up period To describe concomitant medication use for AD and selected comorbidities at baseline and over follow-up Describe the incidence of AEs and serious adverse events (SAE) while on systemic treatment Describe the occurrence of AEs and SAEs over the follow-up period	—

Measure

Time frame

To describe participant sociodemographic and clinical characteristics at baseline To describe quality of life, depression, productivity, and treatment satisfaction while being treated with systemic therapy for AD using PROs from baseline and over follow-up To describe health care resource utilization from baseline and over the follow-up period To evaluate selected comorbid atopic and non-atopic conditions at baseline and over the follow-up period To describe concomitant medication use for AD and selected comorbidities at baseline and over follow-up Describe the incidence of AEs and serious adverse events (SAE) while on systemic treatment Describe the occurrence of AEs and SAEs over the follow-up period

—

Countries

Canada, China, France, Germany, Italy, Japan, Saudi Arabia, Spain, United Arab Emirates, United States

Contacts

Public ContactWaka Shimomoto

IQVIA Services Japan G.K.

waka.shimomoto@iqvia.com+81-90-8655-6223

Outcome results